NOX-700

DB05464ExperimentalSmall molecule

NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). In animal studies, NOX-700 lowered serum... In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.

Mechanism: It has been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus (type 2).Curator reviewed
Code names: NOX-700

Resolves to

Targets

Q00653NFKB2P19838NFKB1

What you can answer from here — as of April 02, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with NOX-700, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account